Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Pfizer's (NYSE: PFE ) been all too happy to get rid of its peripheral businesses in the recent past, spinning off its animal health business in early 2013 after selling its infant nutrition group back in 2012. It's paid off in a big way for investors, who have made the most of Pfizer's stock surge over the past year. Could Pfizer be ready to divest yet another business in 2014?
Generic drugmakers are reportedly lining up for just that possibility. According to a recent Reuters report, Mylan (NASDAQ: MYL ) , Actavis (NYSE: ACT ) , and Valeant Pharmaceuticals (NYSE: VRX ) are all circling Pfizer's generics business now that the big pharma company's finished reorganizing. Pfizer's made no secret about its goal of honing in on its core branded pharmaceuticals business, and these three generics suitors all have been on the acquisitions train as of late.
Yet would Pfizer's lucrative generics business make sense for these suitors? In the video below, Motley Fool contributor Dan Carroll digs into the reported interest of these companies in a buy -- and how such a deal between Pfizer and one of these big names could mean big money for investors in the near future.
The tools you need to spark your financial future
Pfizer's hoping to keep its stock surge going in the new year, but have you made the most of the market's rally? Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.